Praxis Precision Medicines, Inc.
NASDAQ:PRAXBiotechnology
Healthcare
$310.90 +4.49%
+$12.13 today
- Market cap
- $8.69B
- Beta
- 2.75
- P/E (TTM)
- -25.0
- EPS (TTM)
- -$11.31
52W Low $37.19High $366.52
Volume 0.63M
Average 0.45M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$326.20M
FY 2025 · Annual
Net Income
-$303.27M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 2.45M | 8.55M | 0 |
| Cost of Revenue | 0 | 154.44M | 86.77M | 152.41M | 140K |
| Gross Profit | 0 | (154.44M) | (84.32M) | (143.86M) | (140K) |
| Gross Margin | — | — | -3445.8% | -1682.0% | — |
| Research & Development | 120.26M | 155.04M | 86.77M | 152.41M | 267.12M |
| Selling, General & Admin | 47.08M | 59.55M | 42.05M | 56.31M | 59.08M |
| Operating Expenses | 167.33M | 60.55M | 42.05M | 56.31M | 326.06M |
| Depreciation & Amortization | 182K | 419K | 432K | 358K | 140K |
| EBITDA | (166.88M) | (213.57M) | (122.85M) | (182.46M) | (303.13M) |
| EBITDA Margin | — | — | -5020.2% | -2133.3% | — |
| Operating Income | (167.33M) | (214.99M) | (126.37M) | (200.17M) | (326.2M) |
| Operating Margin | — | — | -5164.4% | -2340.3% | — |
| Interest Income | 0 | 0 | 0 | 17.35M | 22.93M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 271K | 957K | 3.1M | 17.35M | 22.93M |
| Income Before Tax | (167.06M) | (214.03M) | (123.28M) | (182.82M) | (303.27M) |
| Pre-Tax Margin | — | — | -5037.9% | -2137.5% | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (167.06M) | (214.03M) | (123.28M) | (182.82M) | (303.27M) |
| Net Margin | — | — | -5037.9% | -2137.5% | — |
| EPS (Basic) | (58.96) | (69.33) | (18.69) | (10.21) | (13.48) |
| EPS (Diluted) | (58.96) | (69.33) | (18.69) | (10.21) | (13.48) |
| 2.83M | 3.07M | 6.59M | 17.91M | 22.5M | |
| 2.83M | 3.07M | 6.59M | 17.91M | 22.5M |
PRAX Earnings Waterfall · TTM
NASDAQ:PRAX · Revenue to Net Income
Key Ratios
EPS$-12.80
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-24.5
P/S Ratio0.0
Analysis
$0 of revenue converted into -$359.4M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-12.80, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 12, 2026 | |
| 10-Q | Quarterly report | Nov 9, 2026 | |
| 8-K | Current report | Nov 9, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 5, 2026 | |
| SC 13G/A | SC 13G/A filing | Aug 14, 2026 |
How much revenue does PRAX generate?
Praxis Precision Medicines, Inc. (PRAX) reported $0.00 of revenue in fiscal 2025.
Is PRAX profitable?
Praxis Precision Medicines, Inc. (PRAX) reported -$303.27M of net income.
Continue the stock analysis
Jump to another research area for this company.